PALO ALTO, Calif., April 30 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA - News), an emerging pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions utilizing the Company's Staccato® system, announced today that its underwriters exercised their over-allotment option in full to purchase an additional 900,000 shares of its common stock in connection with its previously announced public offering that priced on April 26, 2007. Including the over-allotment shares sold, the Company sold 6,900,000 shares at a public offering price of $10.25 per share, resulting in expected net proceeds to the Company of approximately $66.0 million (after deduction of the underwriting discounts and commissions, and estimated offering expenses).
